Get started
Author

Maria Virginia Bluthgen

Observed names: M. Bluthgen, M.V. Bluthgen, Maria-Virginia Bluthgen, Marie-Virginia Bluthgen, María Virginia Bluthgen, Virginia Bluthgen
Institution: Hospital Alemán
Observed institutions: Université Paris-Saclay, Institut Gustave Roussy, Azienda Ospedaliera Universitaria Integrata Verona, Hospital Clínic de Barcelona, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Hospital Alemán, Fondation Gustave Roussy
ORCID: 0000-0001-5343-218X
Observed ORCID: 0000-0001-5343-218X
OpenAlex ID: A5045568166
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
2015 · Oliver Gautschi, Julie Milia, et al. · Journal of Thoracic Oncology · 188
PDF
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
2017 · J. Remon, C. Caramella, et al. · Annals of Oncology · 171
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
2017 · Francesco Facchinetti, Maria Virginia Bluthgen, et al. · Lung Cancer · 111
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
2017 · C.R. Lindsay, V. Faugeroux, et al. · Annals of Oncology · 94
PDF
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
2019 · Isabelle Rouquette, Estelle Taranchon-Clermont, et al. · Biomarker Research · 52
PDF
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience
2016 · M.V. Bluthgen, C. Boutros, et al. · Lung Cancer · 30
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma
2020 · Alison Dormieux, Laura Mezquita, et al. · European Radiology · 27
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
2015 · Maria-Virginia Bluthgen, Benjamin Besse · European Respiratory Review · 25
PDF
Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC)
2016 · J. Lahmar, L. Mezquita, et al. · Annals of Oncology · 15
Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France
2020 · Nicolas Noël, Audrey Le Roy, et al. · Autoimmunity Reviews · 10
PDF
Immunotherapy Combinations for the Treatment of Patients with Solid Tumors
2020 · Maria Virginia Bluthgen, Neus Basté, et al. · Future Oncology · 8
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients
2017 · Laura Mezquita, Melinda Charrier, et al. · Lung Cancer · 8
3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC)
2015 · C. Caramella, M.V. Bluthgen, et al. · European Journal of Cancer · 8
FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
2021 · F. Blanc-Durand, X. Mielgo Rubio, et al. · Journal of Thoracic Oncology · 4
PDF
3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC)
2015 · M.V. Bluthgen, C. Caramella, et al. · European Journal of Cancer · 4
Thymic malignancies: Moving forward with new systemic treatments
2016 · J. Remon, C.R. Lindsay, et al. · Cancer Treatment Reviews · 3
MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients
2019 · L. Mezquita, I. Gataa, et al. · Journal of Thoracic Oncology · 2
Targeted Therapy for Braf-Mutant Lung Cancer: Results from the European Euraf Cohort Study
2015 · O. Gautschi, M.V. Bluthgen, et al. · Annals of Oncology · 2
PDF
P1.16-10 Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
2019 · A. Kuzminin, N. Minatta, et al. · Journal of Thoracic Oncology · 1
PDF
Trayectoria de Pacientes, Patrones de Tratamiento y Utilización de Recursos Sanitarios en Estadios Tempranos de NSCLC en Argentina
2026 · Martín Pitzzu, Álvaro Romera, et al. · Oncología Clínica
PDF
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease
2024 · Elia Seguí, Juan Torres Canizales, et al. · Cancers
PDF
Caracterización molecular por secuenciación de nueva generación obtenida en biopsia líquida en una cohorte multicéntrica de pacientes con diagnóstico de cáncer de pulmón avanzado en Argentina
2022 · Martina Spotti, José N. Minatta, et al. · Oncología Clínica
PDF
P1.12-04 The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers
2022 · E. Seguí, T. Gorria, et al. · Journal of Thoracic Oncology
PDF
Effect of age on completion of intraperitoneal chemotherapy in ovarian cancer
2016 · M. Tamburelli, M.V. Bluthgen, et al. · Annals of Oncology
PDF
Abstract 2254: Variations in the epithelial-mesenchymal transition (EMT) program by non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) do not influence survival
2016 · Colin R. Lindsay, Vincent Faugeroux, et al. · Cancer Research
Works count: 25
Citation count: 763
H-index: 10
I10-index: 10
Year
Topic
Type